Barinthus Biotherapeutics plc.

Barinthus Biotherapeutics plc. (VACC) priced its initial public offering on Apr 30, 2021 at $17.00 per ADS, within its $16.00–$18.00 range, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $579.1M. Morgan Stanley was lead-left underwriter, joined by Jefferies, Barclays and William Blair and others. Goodwin Procter advised the company and Davis Polk advised the underwriters.

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing immunotherapeutics and vaccines for infectious diseases and cancer. Its proprietary platform produces candidates designed to induce strong, targeted T cell responses against pathogens and tumor cells.

Status

IPO

Ticker

VACC

Exchange

Nasdaq Global Market

Priced

Apr 30, 2021

IPO price

$17.00 per ADS

Price range

$16.00–$18.00

Market cap at IPO price

$579.1M

First filed

Apr 9, 2021

Underwriters

Morgan Stanley, Jefferies, Barclays, William Blair and H.C. Wainwright

Company counsel

Goodwin Procter

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Country / state

MD

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.